HIV Weight Gain and Semaglutide

Weight gain in people with HIV can involve more than a change on the scale. A 2026 review describes changes in fat distribution and fat-tissue biology in people receiving antiretroviral therapy, with visceral fat linked to cardiometabolic risk. Semaglutide has been tested in one small, HIV-specific randomised trial, but it is not a substitute for working through the possible causes of weight and body-composition change with an HIV care team.^[1]

Weight gain and fat distribution are different questions

Body weight is the total number on a scale. Adipose tissue is body fat, and visceral adipose tissue is fat stored around internal organs. HIV-associated lipohypertrophy refers to an abnormal accumulation of abdominal visceral fat. The distinction matters because a person can be concerned about central fat accumulation even when a scale alone does not describe the change well.^[2]

The recent review behind this brief connects weight gain and adipose-tissue remodeling, meaning changes in the structure and function of fat tissue, with HIV infection and with some modern antiretroviral therapy regimens. It discusses dolutegravir, bictegravir and tenofovir alafenamide, while also stressing that higher visceral adiposity is associated with insulin resistance, diabetes, metabolic dysfunction-associated steatotic liver disease and cardiovascular disease.^[1]

That is an association and a clinical problem to assess, not proof that one medicine explains every person's weight change. The review draws on preclinical work and studies of people with controlled HIV, so its proposed mechanisms should not be treated as a diagnosis for an individual.

What the HIV-specific semaglutide trial found

The strongest direct evidence here is a single-centre, phase 2b trial in 108 adults with controlled HIV, lipohypertrophy and a body-mass index of at least 25 kg/m², without type 1 or type 2 diabetes. Participants were randomly assigned to semaglutide or placebo for 32 weeks. The trial reported a 30.6% relative reduction in abdominal visceral adipose tissue with semaglutide versus placebo, alongside reductions in abdominal subcutaneous fat and total body fat.^[2]

Those findings concern a selected group with HIV-associated lipohypertrophy, not every person living with HIV or every person seeking weight management. The study also observed one semaglutide-related grade 4 lipase elevation and two possibly related cases of gallstones. Its authors called for larger studies to clarify the safety signal.^[2]

A later analysis of the same 108-person trial found lower C-reactive protein, interleukin-6 and soluble CD163 after 32 weeks of semaglutide. These are laboratory markers associated with inflammation or immune activation. The analysis did not show changes in circulating monocyte proportions or T-cell phenotypes, and it calls for further work in people with HIV.^[3]

Why a general semaglutide page is only a starting point

Semaglutide is a GLP-1 receptor agonist, a medicine class that acts on a receptor involved in appetite and glucose regulation. In the European Union, Wegovy is an authorised semaglutide medicine for weight management alongside a reduced-calorie diet and physical activity in specified patient groups. That authorisation does not answer whether semaglutide is appropriate for HIV-associated lipohypertrophy or for a particular antiretroviral regimen.^[4]

The distinction is practical. General obesity trials and product information tell readers what a licensed medicine is and how it has been studied in its approved populations. The HIV-specific trial is narrower and shorter. Anyone comparing that evidence with broader information on semaglutide regulation should keep the population, outcome and follow-up period in view.^{[2] [4]}

What clinicians may need to sort out

A useful discussion starts with the timeline: when weight or waist measurements changed, the current and previous antiretroviral regimen, other medicines, sleep, diet, activity, alcohol use and relevant metabolic measurements. The 2026 review notes that switching antiretroviral regimens and anti-obesity medicines have both been examined as ways to address ART-associated weight gain, but neither is a universal answer.^[1]

It also makes sense to separate goals. A person may be trying to address overall weight, abdominal fat distribution, glucose measures, lipids, blood pressure or medication tolerability. Those goals can overlap, but the available HIV trial was designed around changes in adipose-tissue compartments over 32 weeks, not long-term prevention of cardiovascular events.

What we do not know yet

We do not yet have large, long-term trials showing that semaglutide prevents cardiovascular events in people with HIV-associated lipohypertrophy. We also do not know whether the results from one US centre apply across HIV populations, antiretroviral regimens or care settings. The trial supports a focused research question. It does not establish a dosing plan or a replacement for individualized HIV and metabolic care.^[2]

For readers, the sensible takeaway is narrower than the headline. Semaglutide has promising phase 2 evidence for reducing visceral fat in a defined HIV-associated lipohypertrophy population. The next question is whether that evidence fits a person's own clinical picture, medications and risks. A qualified clinician who knows the HIV regimen is the right place to start.^{[1] [2]}